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Identification of Histone H4-Based Peptoids as Inhibitors of 
PRMT1
 Enzymes bind with substrates in the active
site. The active site is composed of unique
amino acid residues which create a specific,
ideal environment. This enzyme-substrate
complex is formed via a lock and key model
shown below.
 PRMTs post translationally modify arginine
residues by methylating its histone tails.
PRMT1 produces ADMA, while PRMT5
produces SMDA.
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Protein Arginine Methyltransferases (PRMTs) are a family of 11 mammalian enzymes characterized by the post-translational methylation of arginine residues in the histone tail. The majority of the 11 members of the PRMT family are divided into two main types, Type I and Type II. PRMT1, the
major Type I isozyme, catalyzes the formation of asymmetrically dimethylated arginine (ADMA). PRMT1 activates transcription of cancer genes. Peptoids, or poly-N-substituted glycine's are a class of oligomers whose side chains are appended to the nitrogen atom of the peptide backbone rather
than the alpha carbon. Kinetic parameters were conducted for both peptide and peptoid sequences. The Kcat/Km and IC50 values determined that peptoids show inhibition activity. The specificity and location of these interactions are currently being determined by altering the residues of a known
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General Peptidomimetics
• Peptoids are similar to peptides 
but differ in the location of the 
side chain. Peptoids have high 
bio stability because they are not 
susceptible to proteases.  
 PRMT1 can activate transcription of
cancer-related genes. Inhibition of
PRMT1 would be beneficial to repress
activation of these cancer-related genes












































































































Kinetic parameters of selected peptides​
Peptide​ kcat(min-1) Km(µM)​ Kcat/Km(M-1min-1) 
AcH4-21​ 3.55 ± 0.68​ 0.39 ± 0.01​ 1.10 × 105
AcH4-16​ 152 ± 14​ 0.28 ± 0.01​ 1.82 × 103
AcH4-13​ 365 ± 174​ 0.18 ± 0.05​ 4.94 × 102
aThese values were reported in Osborne et all. The SAM concentration for 
determining these values was 15 µM.
IC50 values of peptoids​
Acetylated Peptoids​ Unacetylated Peptoids​
Peptoid​ IC50 (µM)​ Peptoid​ IC50(µM)​
AcH4-16​ 916 ± 19.5​ H4-16​ 396 ± 31.4​
AcH4-13​ >1000 H4-13​ 898±93.5​
AcH4-8​ >1000 H4-8​ >1000 







 The amines that were not commercially 
available were synthesized. These include N-
Lysine, N-Serine, N-Arginine and N-Leucine, 






H4-16 K12A  K16A AAGGAGLGKGGKGRGS
Conclusions
We were able to identify a novel PRMT inhibitor. Advantages of this inhibitor are that it is resistant to 
proteases due to the peptoid structure and the fact that it lacks peptide bonds. This inhibitor is likely a 
competitive inhibitor and may be specific to PRMT1. 
Future Directions
• Determine the kinetic parameters and IC50
values for the three H4-16 peptoids. 
• We also plan on testing the H4-16 peptoid as a 
possible inhibitor for PRMT5
• Determine the the type of inhibition
• Determine the binding site for the H4-16 peptoid
Acknowledgements
Kinetic parameters of peptoids​
Peptoid​ kcat(min-1) Km(µM)​ Kcat/Km(M-1min-1) 
AcH4-16​ nda nda nda
AcH4-13​ nda nda nda
AcH4-8​ nda nda nda
aThe kinetic parameters for these compounds were not determined due to a 
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